# reload+after+2024-01-21 21:44:50.155766
address1§3675 Market Street
city§Philadelphia
state§PA
zip§19104
country§United States
phone§215 921 7600
fax§215 921 7900
website§https://amicusrx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
fullTimeEmployees§484
companyOfficers§[{'maxAge': 1, 'name': 'Mr. John F. Crowley', 'age': 56, 'title': 'Executive Chairman', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 1878804, 'exercisedValue': 0, 'unexercisedValue': 3203616}, {'maxAge': 1, 'name': 'Mr. Bradley L. Campbell M.B.A.', 'age': 47, 'title': 'CEO, President & Director', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 984087, 'exercisedValue': 461214, 'unexercisedValue': 3854297}, {'maxAge': 1, 'name': 'Ms. Ellen S. Rosenberg', 'age': 60, 'title': 'Chief Legal Officer & Corporate Secretary', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 733943, 'exercisedValue': 0, 'unexercisedValue': 1730125}, {'maxAge': 1, 'name': 'Mr. David M. Clark', 'age': 48, 'title': 'Chief People Officer', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 701389, 'exercisedValue': 0, 'unexercisedValue': 341111}, {'maxAge': 1, 'name': 'Dr. Jeffrey P. Castelli', 'age': 51, 'title': 'Chief Development Officer', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 709644, 'exercisedValue': 88607, 'unexercisedValue': 543184}, {'maxAge': 1, 'name': 'Mr. Simon Nicolas Reade Harford', 'age': 62, 'title': 'Chief Financial Officer', 'yearBorn': 1961, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Samantha  Prout', 'age': 45, 'title': 'Chief Accounting Officer & Controller', 'yearBorn': 1978, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jill  Weimer Ph.D.', 'title': 'Chief Science Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Andrew  Faughnan', 'title': 'Senior Director of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Patrik S. Florencio Esq.', 'title': 'Global Chief Compliance & Risk Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§5
compensationRisk§5
shareHolderRightsRisk§7
overallRisk§6
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.844
priceToSalesTrailing12Months§10.647169
currency§USD
dateShortInterest§1702598400
forwardEps§0.07
pegRatio§0.2
exchange§NGM
quoteType§EQUITY
shortName§Amicus Therapeutics, Inc.
longName§Amicus Therapeutics, Inc.
firstTradeDateEpochUtc§1180618200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§18ecfd93-9817-3a94-a13a-c6019ef27903
gmtOffSetMilliseconds§-18000000
targetHighPrice§21.0
targetLowPrice§15.0
targetMeanPrice§19.33
targetMedianPrice§20.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§9
quickRatio§2.087
grossMargins§0.90497
ebitdaMargins§-0.27807
trailingPegRatio§None
